Mizuho Securities Downgrades Valeant Pharmaceuticals (VRX) to Underperform
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Mizuho Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underperform with a price target of $11.00 (from $25.00).
Analyst Irina Koffler said, "We believe the risk/reward is unfavorable due to growth challenges, 2017 guidance risk, legal overhangs, and weaker asset divestitures. While we see no impending sell catalyst, we believe this stock will edge lower over the next 6-12 months as investor patience wanes. We downgrade to Underperform from Neutral, and lower our PT to $11 from $25."
Shares of Valeant Pharmaceuticals closed at $17.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades NantKwest (NK) to Hold
- Facebook (FB) Q4 Estimates, PT Raised At Jefferies
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades, Hot Downgrades
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!